Skip to content
Peptide research

Gonadorelin

Also known as Factrel · Lutrepulse · GnRH
Category
Hormone & Sexual Health
Administration routes
Injectable
Regulatory status
Not FDA-approved

A synthetic form of GnRH, well studied for triggering LH and FSH release to induce ovulation and test pituitary function. Its trendy longevity-clinic use, preserving testicular function during TRT, is speculative and unproven in humans. The key risk is dosing: continuous, non-pulsatile use paradoxically shuts down the axis it's meant to stimulate, and rare anaphylaxis is reported. Not FDA-approved for that use; supply is compounded or research-grade.

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.

Overview

Gonadorelin is a synthetic peptide that is identical to your body's own gonadotropin-releasing hormone (GnRH), the 10-amino-acid master signal that controls reproductive hormone production. It acts on the pituitary gland to stimulate the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). Originally sold as Factrel and Lutrepulse (both now discontinued in the US), gonadorelin has re-emerged as a compounded medication, particularly as a replacement for HCG in testosterone replacement therapy protocols after the FDA reclassified HCG as a biologic in 2020.

How it works in the body

A synthetic version of gonadotropin-releasing hormone (GnRH). It binds to GnRH receptors on pituitary gonadotroph cells, triggering the release of LH and FSH. These hormones then stimulate the gonads to produce testosterone (men) or estrogen and progesterone (women), maintaining natural hormonal feedback.

Research overview

Gonadorelin is one of the best-characterized peptide hormones in medicine, with decades of research dating back to the Nobel Prize-winning work of Andrew Schally and Roger Guillemin in the 1970s. It has a very short half-life of about 2-4 minutes in the bloodstream, meaning it must be given in pulses to mimic the body's natural signaling rhythm. Clinical evidence strongly supports its ability to induce ovulation in women with hypothalamic amenorrhea (91-96% success rate) and to stimulate sperm production in men with congenital hormone deficiencies. Its newer role as an HCG alternative during testosterone therapy has less robust evidence, with mixed results regarding its ability to preserve testicular function and fertility while on exogenous testosterone.

Who researches Gonadorelin?

Commonly researched by

  • People exploring hormone and sexual health

    Researched for effects on hormone levels, sexual function, or fertility.

  • People researching stimulates endogenous lh and fsh production

    One of the primary studied benefits of Gonadorelin.

Important considerations for

  • Those with Hormone-sensitive cancers (prostate, breast)

    High

    Initial LH/FSH surge can temporarily increase sex hormone levels before suppression.

  • Those who are pregnant or breastfeeding

    Absolute

    Can disrupt pregnancy hormones.

Safety & interactions

Do not use if

  • Hormone-sensitive cancers (prostate, breast)

    High

    Initial LH/FSH surge can temporarily increase sex hormone levels before suppression.

General cautions

  • Pregnancy

    Absolute

    Can disrupt pregnancy hormones.

How to read the ratings

Benefits
= confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Risks
= level of concern: High · Moderate · Low · Theoretical
Interactions
= direction with this peptide: Protective / Synergistic · Caution · Neutral

Risk summary(13)

Rated by level of concern

  • Headache, nausea, lightheadedness, and abdominal discomfort (uncommon)

    Low

    Factrel labeling — https://www.rxlist.com/factrel-drug.htm

  • Injection site reactions including pain, swelling, induration, and pruritus

    Low

    Lutrepulse product monograph, adverse reactions — https://www.ferring.ca/media/1230/lutrepulse-pm-control-no-127836-3-2mg-and-0-8-mg-en_17aug2010.pdf ; Factrel labeling — https://www.rxlist.com/factrel-drug.htm (induration at injection site)

  • Hypersensitivity/anaphylactic reactions (rare but reported; caution on re-administration)

    Moderate

    Factrel labeling — https://www.rxlist.com/factrel-drug.htm ; Lutrepulse product monograph — https://www.ferring.ca/media/1230/lutrepulse-pm-control-no-127836-3-2mg-and-0-8-mg-en_17aug2010.pdf (frequency categories)

  • Flushing and tachycardia (rare)

    Low

    Factrel labeling — https://www.rxlist.com/factrel-drug.htm ; Lutrepulse product monograph — https://www.ferring.ca/media/1230/lutrepulse-pm-control-no-127836-3-2mg-and-0-8-mg-en_17aug2010.pdf

  • Bronchospasm (rare)

    Low

    Factrel labeling — https://www.rxlist.com/factrel-drug.htm ; Lutrepulse product monograph — https://www.ferring.ca/media/1230/lutrepulse-pm-control-no-127836-3-2mg-and-0-8-mg-en_17aug2010.pdf

  • Multiple pregnancy risk when used for ovulation induction (12% incidence in clinical trials)

    High

    Lutrepulse product monograph, adverse reactions — https://www.ferring.ca/media/1230/lutrepulse-pm-control-no-127836-3-2mg-and-0-8-mg-en_17aug2010.pdf (11/89 = 12%)

  • Ovarian hyperstimulation syndrome (rare, especially with concurrent clomiphene)

    Low

    Lutrepulse product monograph — https://www.ferring.ca/media/1230/lutrepulse-pm-control-no-127836-3-2mg-and-0-8-mg-en_17aug2010.pdf (1/268, clomiphene co-treatment, <1%)

  • Antibody formation with repeated administration (rare)

    Low

    Lutrepulse product monograph — https://www.ferring.ca/media/1230/lutrepulse-pm-control-no-127836-3-2mg-and-0-8-mg-en_17aug2010.pdf (~3% with SC FACTREL) ; Factrel labeling — https://www.rxlist.com/factrel-drug.htm (antibody formation after chronic administration)

  • Risk of pituitary apoplexy if administered to patients with undiagnosed pituitary adenoma

    Low

    Factrel labeling — https://www.rxlist.com/factrel-drug.htm (pituitary apoplexy/sudden blindness as a rare case report)

  • Menorrhagia (frequency unknown)

    Theoretical

    Authorized UK gonadorelin product information, section 4.8, lists menorrhagia with frequency unknown: https://www.medicines.org.uk/emc/product/4853/smpc

  • Paradoxical pituitary downregulation with continuous (non-pulsatile) high-dose administration

    High

    Lutrepulse product monograph, overdosage/pharmacology — https://www.ferring.ca/media/1230/lutrepulse-pm-control-no-127836-3-2mg-and-0-8-mg-en_17aug2010.pdf (continuous non-pulsatile exposure can temporarily reduce pituitary responsiveness). Prior apoplexy PubMed link removed - it did not support this claim.

  • Potential worsening of hormone-dependent tumors due to initial gonadotropin surge

    Theoretical

    Extrapolated from GnRH agonist flare literature; no gonadorelin-specific evidence identified

  • Skin allergic reactions at pump infusion site (noted in pulsatile pump studies)

    Low

    Lutrepulse product monograph, adverse reactions and frequency table — https://www.ferring.ca/media/1230/lutrepulse-pm-control-no-127836-3-2mg-and-0-8-mg-en_17aug2010.pdf

Interaction summary(8)

Rated by direction with this peptide

  • GnRH agonists and antagonists (leuprolide, goserelin, cetrorelix, ganirelix)

    CautionModerate

    These act at the same receptor - antagonists block it and agonists downregulate the gonadotroph - so co-administration abolishes or invalidates gonadorelin's LH/FSH response. The consequence is loss of effect or an uninterpretable diagnostic test, not direct toxicity. This is a mechanism-based inference, not a documented clinical interaction study.

    Mechanism-based inference from GnRH-receptor pharmacology and GnRH agonist/antagonist labeling; no gonadorelin-specific interaction study identified

  • Exogenous sex steroids (androgens, estrogens, progestins, oral contraceptives)

    CautionModerate

    Per the labeling, gonadotropin levels are suppressed by oral contraceptives, and medications containing androgens, estrogens, progestins or glucocorticoids should be avoided during gonadorelin testing, since negative feedback blunts the LH/FSH response and can produce a falsely abnormal result.

    Factrel labeling — https://www.rxlist.com/factrel-drug.htm

  • Dopamine antagonists and phenothiazines (prolactin-raising agents)

    CautionModerate

    Per the labeling, the gonadorelin response may be blunted by phenothiazines and dopamine antagonists that cause a rise in prolactin, since hyperprolactinemia suppresses gonadotroph responsiveness.

    Factrel labeling — https://www.rxlist.com/factrel-drug.htm

  • Clomiphene citrate and other ovarian stimulants

    CautionLow

    The evidence is a single case. In 268 women in the pivotal Lutrepulse program, the one reported case of moderate ovarian hyperstimulation occurred with concomitant clomiphene citrate. Biologically plausible and worth monitoring when ovarian stimulants are used together.

    Lutrepulse product monograph — https://www.ferring.ca/media/1230/lutrepulse-pm-control-no-127836-3-2mg-and-0-8-mg-en_17aug2010.pdf (1 case in 268 women, with concomitant clomiphene)

  • Spironolactone

    CautionLow

    Per the labeling, gonadotropin levels may be transiently elevated by spironolactone, which can confound interpretation of a gonadorelin stimulation test. Diagnostic-interpretation issue only, not a safety interaction.

    Factrel labeling — https://www.rxlist.com/factrel-drug.htm

  • Digoxin

    CautionLow

    Per the labeling, gonadotropin levels may be suppressed by digoxin, potentially producing a blunted apparent response to gonadorelin. Diagnostic-interpretation issue only.

    Factrel labeling — https://www.rxlist.com/factrel-drug.htm

  • Levodopa

    CautionLow

    Per the labeling, gonadotropin levels may be minimally elevated by levodopa; the effect is small but relevant to diagnostic test interpretation.

    Factrel labeling — https://www.rxlist.com/factrel-drug.htm

  • Glucocorticoids

    CautionLow

    Per the labeling, preparations containing glucocorticoids (alongside androgens, estrogens and progestins) should be avoided during gonadorelin testing because they directly affect pituitary gonadotropin secretion. Diagnostic-interpretation issue only.

    Factrel labeling — https://www.rxlist.com/factrel-drug.htm

Known risks(13)

  • Headache, nausea, lightheadedness, and abdominal discomfort (uncommon)

  • Injection site reactions including pain, swelling, induration, and pruritus

  • Hypersensitivity/anaphylactic reactions (rare but reported; caution on re-administration)

  • Flushing and tachycardia (rare)

  • Bronchospasm (rare)

  • Multiple pregnancy risk when used for ovulation induction (12% incidence in clinical trials)

  • Ovarian hyperstimulation syndrome (rare, especially with concurrent clomiphene)

  • Antibody formation with repeated administration (rare)

  • Risk of pituitary apoplexy if administered to patients with undiagnosed pituitary adenoma

  • Menorrhagia (frequency unknown)

  • Paradoxical pituitary downregulation with continuous (non-pulsatile) high-dose administration

  • Potential worsening of hormone-dependent tumors due to initial gonadotropin surge

  • Skin allergic reactions at pump infusion site (noted in pulsatile pump studies)

Drug interactions(10)

  • Androgens (testosterone, nandrolone, etc.)

    Suppress pituitary gonadotropin secretion via negative feedback, reducing response to gonadorelin diagnostic test; therapeutic interaction is the basis for using gonadorelin as a TRT adjunct

  • Estrogens and oral contraceptives

    Suppress gonadotropin levels and blunt the pituitary response to gonadorelin

  • Progestins

    Directly affect pituitary gonadotropin secretion and may alter gonadorelin response

  • Glucocorticoids

    Can suppress the hypothalamic-pituitary-gonadal axis, potentially reducing gonadorelin efficacy

  • Spironolactone

    Transiently elevates gonadotropin levels, potentially enhancing gonadorelin response

  • Digoxin

    Suppresses gonadotropin levels, reducing response to gonadorelin

  • Phenothiazines and dopamine antagonists

    Cause elevated prolactin levels which blunt the pituitary response to gonadorelin

  • Levodopa

    Minimally elevates gonadotropin levels

  • Clomiphene citrate

    Concurrent use with gonadorelin for ovulation induction may increase risk of ovarian hyperstimulation syndrome

  • GnRH agonists/antagonists (leuprolide, goserelin, cetrorelix, degarelix)

    Compete for or modulate GnRH receptors; concurrent use is contraindicated as it will interfere with gonadorelin action

Research & benefits

Evidence base

Evidence Level
Level 1-2 — Strong
Total Studies
Hundreds of published studies on GnRH physiology and clinical applications
Human Studies
Extensive human data from clinical trials, diagnostic use, and fertility treatment spanning 50+ years

Gonadorelin has decades of Level I-II evidence for ovulation induction in hypothalamic amenorrhea and spermatogenesis induction in hypogonadotropic hypogonadism. The diagnostic GnRH stimulation test is a well-validated clinical tool. Its use as an HCG alternative in TRT protocols is supported by mechanistic rationale and clinical experience but lacks large randomized controlled trials.

Researched for(6)

Rated by confidence in the evidence

  • Stimulates endogenous LH and FSH production

    High

    Reproducible, dose-dependent LH and FSH rise in humans, basis of an FDA-approved diagnostic test.

    Factrel (gonadorelin HCl) labeling summary via RxList — https://www.rxlist.com/factrel-drug.htm (indications and pharmacology) ; Lutrepulse (gonadorelin acetate) product monograph — https://www.ferring.ca/media/1230/lutrepulse-pm-control-no-127836-3-2mg-and-0-8-mg-en_17aug2010.pdf

  • Induces ovulation in hypothalamic amenorrhea

    High

    Approved therapy; pulsatile dosing produced ovulation in about 94-96% of women in clinical trials.

    Lutrepulse (gonadorelin acetate) product monograph, trial results — https://www.ferring.ca/media/1230/lutrepulse-pm-control-no-127836-3-2mg-and-0-8-mg-en_17aug2010.pdf (268 women, 94%/96% ovulation rates, 142 pregnancies)

  • Stimulates spermatogenesis in hypogonadotropic hypogonadism

    Medium

    Pulsatile GnRH pump therapy induced sperm production in about 61% of men in a 2024 study.

    Arch Endocrinol Metab 2024, pulsatile GnRH for spermatogenesis after poor gonadotropin response — https://pmc.ncbi.nlm.nih.gov/articles/PMC11156179/ (17/28 = 60.7%); Reprod Biol Endocrinol 2025, pulsatile GnRH vs combined gonadotropin — https://link.springer.com/article/10.1186/s12958-025-01370-7

  • Diagnostic evaluation of pituitary function

    Medium

    FDA-approved test to assess pituitary gonadotrope response, though it cannot pinpoint the cause alone.

    Factrel (gonadorelin HCl) labeling summary — https://www.rxlist.com/factrel-drug.htm (indications)

  • Potential preservation of testicular function during TRT

    Speculative

    No published human trials; rationale relies on mechanism and analogy to hCG therapy.

    No primary trial identified; claim rests on mechanism and hCG-analogy only

  • More physiologic hormonal stimulation than HCG

    Low

    Mechanistically plausible and suggested by non-randomized human data, but no head-to-head trial confirms it.

    Lutrepulse product monograph, mechanism/comparison with hMG — https://www.ferring.ca/media/1230/lutrepulse-pm-control-no-127836-3-2mg-and-0-8-mg-en_17aug2010.pdf ; Arch Endocrinol Metab 2024 — https://pmc.ncbi.nlm.nih.gov/articles/PMC11156179/ (greater testicular volume increase on pulsatile GnRH).

Benefits(6)

  • Stimulates endogenous LH and FSH production

    Well-established mechanism confirmed in extensive clinical research since the 1970s; pulsatile release pattern differentially regulates LH (fast pulses) vs FSH (slow pulses)

  • Induces ovulation in hypothalamic amenorrhea

    Multicenter clinical trial (Santoro 1990, PMID 2122733): 91% ovulation rate in primary amenorrhea, 96% in secondary amenorrhea among 109 women

  • Stimulates spermatogenesis in hypogonadotropic hypogonadism

    Zhang et al. 2018 (PMC6775549): Pulsatile gonadorelin pump achieved 90% spermatogenesis rate with median onset of 6 months vs 14 months for gonadotropin therapy

  • Diagnostic evaluation of pituitary function

    FDA-approved use (Factrel): A single bolus injection with serial LH measurements assesses pituitary gonadotrope responsiveness; the single-injection test cannot determine the cause of a subnormal response on its own.

  • Potential preservation of testicular function during TRT

    Used in clinical practice as HCG alternative since 2020; evidence is mixed — may help reduce testicular atrophy but does not reliably maintain intratesticular testosterone in all patients

  • More physiologic hormonal stimulation than HCG

    Works through natural HPG axis signaling rather than direct gonadal stimulation; produces more stable testosterone levels compared to gonadotropin therapy (Zhang et al. 2018)

Key studies(5)

  1. Santoro N

    American Journal of Obstetrics and Gynecology

    1990

    Pulsatile GnRH achieved 91% ovulation in primary and 96% in secondary hypothalamic amenorrhea, with comparable efficacy to hMG and reduced risks

  2. Zhang L, Cai K, Wang Y, Ji W, Cheng Z, Chen G, Liao Z

    American Journal of Men's Health

    2018

    Pulsatile gonadorelin pump induced spermatogenesis at median 6 months vs 14 months for cyclical gonadotropin therapy (p=0.01); 90% vs 83.3% spermatogenesis rates

  3. Physiology, Gonadotropin-Releasing Hormone

    Comprehensive ReviewN/A (review)

    Stamatiades GA, Kaiser UB (referenced); StatPearls comprehensive review

    StatPearls / NCBI Bookshelf

    2024

    GnRH pulsatile secretion pattern differentially regulates LH (fast pulses) vs FSH (slow pulses); half-life 2-4 minutes; acts via Gq-coupled GnRHR activating PLC/IP3/DAG/PKC signaling cascade

  4. Physiology of GnRH and Gonadotrophin Secretion

    Comprehensive ReviewN/A (review)

    Marques P, et al.

    Endotext / NCBI Bookshelf

    2024

    Comprehensive review of GnRH neurobiology, KNDy neuronal regulation (kisspeptin/neurokinin B/dynorphin), and clinical applications in reproductive medicine

  5. Effectiveness and safety of pulsatile GnRH pump therapy on female patients with IHH

    Clinical StudyFemale patients with idiopathic hypogonadotropic hypogonadismVariable

    Various (Chinese study)

    PubMed indexed study

    2015

    Pulsatile GnRH pump therapy demonstrated effectiveness and safety for inducing puberty and fertility in female IHH patients

What research suggests over time

  • Weeks 2-4

    Decades of clinical use

    Pulsatile dosing restores physiologic LH/FSH pulses; testicular volume or follicular development begins responding within days.

  • Months 2-3

    Level I clinical

    Ovulation induction in 91% of women with primary hypothalamic amenorrhea (Am J Obstet 1990); follicular development on schedule.

  • Long-term

    Level I clinical

    Pulsatile gonadorelin pump induced spermatogenesis at median 6 months in hypogonadotropic hypogonadism (vs 14 months for cyclical gonadotropin therapy).

Regulation & availability

Why researchers look at it

Surged in demand after HCG was reclassified as a biologic in 2020 and pulled from compounding pharmacies, leaving men on testosterone therapy without their primary fertility-preservation tool. Clinical evidence is strong for its core use — 91-96% ovulation success rates in women with hypothalamic amenorrhea — and growing clinical experience supports its newer role as an HCG substitute during TRT. Large randomized trials for the TRT application are still needed, but if confirmed, gonadorelin could become the standard adjunct in testosterone protocols nationwide.

Estimated cost
$50-150/mo compounding
FDA status
Human Factrel (gonadorelin hydrochloride, NDA 018123) was FDA-approved for diagnostic use in 1982; Lutrepulse Kit (gonadorelin acetate, NDA 019687) was approved in 1989 for pulsatile IV administration to induce ovulation in primary hypothalamic amenorrhea. Both are discontinued in the US, and no currently marketed FDA-approved human formulation exists. Compounded gonadorelin is not FDA-approved; 503A use must meet applicable statutory conditions, and gonadorelin acetate appears in 503B interim-policy Category 1. Veterinary gonadorelin products, including Factrel (NADA 139-237) and Fertagyl (ANADA 200-134), are approved for cattle. Gonadorelin is recognized by the FDA as a known substance (UNII registered: gonadorelin hydrochloride and gonadorelin acetate).
WADA status
PROHIBITED IN MALES — Gonadorelin (GnRH) and its agonist analogues are prohibited at all times under section S2.2.1 of the 2026 WADA Prohibited List, effective January 1, 2026. The listed examples include buserelin, deslorelin, goserelin, histrelin, leuprorelin, nafarelin and triptorelin. Athletes with a legitimate medical need may require a Therapeutic Use Exemption.
Prescribability
Yes — available through compounding pharmacies; branded products (Factrel, Lutrepulse) discontinued in the US
Availability
Branded products discontinued in the US: Factrel (gonadorelin HCl, diagnostic) and Lutrepulse (gonadorelin acetate, pulsatile fertility treatment) are no longer marketed. Currently available through US 503B outsourcing facilities and compounding pharmacies (e.g., Empower Pharmacy, Strive Pharmacy) as compounded gonadorelin for subcutaneous injection, prescribed off-label alongside testosterone therapy as an HCG alternative. Also available internationally: gonadorelin powder for injection (Esteve Pharmaceuticals, UK) for diagnostic use. Veterinary Factrel remains FDA-approved for use in cattle.

International status

  • EU

    Available as prescription medication

  • US

    Previously FDA-approved; available via compounding

  • Australia

    Available via compounding

Regulatory timeline(7)

  1. 1977
    GnRH structure first characterized by Andrew Schally and Roger Guillemin (awarded Nobel Prize in Physiology or Medicine 1977)
  2. 1977
    Synthetic GnRH (gonadorelin) first produced for clinical research
  3. 1982
    Factrel (gonadorelin HCl) approved by FDA for diagnostic evaluation of pituitary gonadotrope function
  4. 1989
    Lutrepulse (gonadorelin acetate) approved by FDA for pulsatile IV administration to induce ovulation in primary hypothalamic amenorrhea
  5. 1999
    Both Factrel and Lutrepulse discontinued from US market due to limited commercial viability and complexity of pulsatile pump administration
  6. 2020-03
    FDA reclassifies HCG as a biologic product; compounding pharmacies can no longer produce HCG, driving adoption of compounded gonadorelin as an alternative in TRT protocols
  7. 2026
    Gonadorelin remains available through 503A/503B compounding pharmacies; no new FDA-approved human formulation. Continued inclusion on WADA Prohibited List (S2 category). Veterinary formulation (Fertagyl) remains FDA-approved for cattle.

Sources & FAQs

Research sources(10)

Frequently asked questions(6)

What is the difference between gonadorelin and HCG?

Gonadorelin (GnRH) works upstream in the hormonal axis — it stimulates the pituitary gland to release LH and FSH naturally, which then signal the testes. HCG mimics LH and directly stimulates the testes. Gonadorelin produces a more physiologic response but requires more frequent dosing than HCG and may be less potent at maintaining intratesticular testosterone levels.

Why did gonadorelin become popular as a TRT adjunct?

In 2020, the FDA reclassified HCG as a biologic product, which meant compounding pharmacies could no longer produce it. Gonadorelin emerged as the primary compounded alternative for men on TRT who wanted to preserve testicular function and fertility.

How is gonadorelin administered?

For diagnostic use: a single IV or SC injection. For fertility treatment (historical): pulses via programmable pump. For TRT adjunct (compounded): subcutaneous injection.

What is the half-life of gonadorelin?

Gonadorelin has an extremely short plasma half-life of approximately 2-4 minutes, with rapid hydrolysis into smaller peptide fragments. The distribution half-life is 2-10 minutes and terminal half-life is 10-40 minutes. This short half-life is why pulsatile pump delivery was developed for therapeutic use.

Is gonadorelin effective for maintaining fertility on TRT?

Evidence is mixed. While gonadorelin stimulates LH/FSH release through natural pathways, its very short half-life means a single daily injection may not provide sustained gonadotropin stimulation. Some clinicians report success in reducing testicular atrophy, but it does not reliably maintain sperm production in all men on TRT. Pulsatile pump delivery would be more physiologic but is impractical for most patients.

Can gonadorelin be used in women?

Yes. Gonadorelin has strong clinical evidence for inducing ovulation in women with hypothalamic amenorrhea (91-96% ovulation rates in clinical trials). It was historically administered via pulsatile pump (Lutrepulse) for this indication. It is also used diagnostically to evaluate pituitary function in both sexes.